Publications by authors named "K Ylaya"
Colorectal carcinoma brain metastases (n = 60) were studied using next-generation sequencing and immunohistochemistry. RAS and BRAF mutations were detected in 58.2% and 7.
View Article and Find Full Text PDFArticle Synopsis
- Epithelial chemosensory cells, called tuft cells, are linked to tumor formation, especially in lung cancers, related to the POU2F3 transcription factor which indicates tuft cell lineage.
- A study analyzed POU2F3 expression in over 8,000 tumor samples, finding positive expression in roughly 12.4% of epithelial tumors and 4.6% of mesenchymal/neuroectodermal tumors, with most neuroendocrine tumors showing strong POU2F3 presence.
- Co-expression of POU2F3 with coactivators like POU2AF2 gives a more specific tumor marker, suggesting that while POU2F3 is sensitive for tuft cell differentiation
Article Synopsis
- Schlafen 11 (SLFN11) is a helicase that regulates how cells respond to stress during DNA replication, and its expression can predict treatment outcomes in cancer patients receiving certain therapies.
- In a study involving 6,658 tumors, SLFN11 was found to be rare in common epithelial tumors (e.g., breast and prostate cancers) but prevalent in several more aggressive tumors and specific mesenchymal and neuroectodermal cancers.
- The absence of SLFN11 may lead to worse outcomes for patients treated with DNA-damaging drugs, suggesting the need for alternative treatments for those cancers that lack this biomarker.
Glypican-3 (GPC3) is overexpressed in hepatocellular carcinomas and hepatoblastomas and represents an important therapeutic target but the biologic importance of GPC3 in liver cancer is unclear. To date, there are limited data characterizing the biological implications of GPC3 knockout (KO) in liver cancers that intrinsically express this target. Here, we report on the development and characterization of GPC3-KO liver cancer cell lines and compare to them to parental lines.
View Article and Find Full Text PDFArticle Synopsis
- Merkel cell carcinoma (MCC) and small cell lung cancer (SCLC) can look similar under a microscope, complicating their diagnosis and requiring specific tests to tell them apart.* -
- Current immunohistochemistry markers like cytokeratin 20 (CK20) and thyroid transcription factor 1 (TTF-1) are commonly used, but have limitations in sensitivity and specificity.* -
- New candidate markers, ATOH1 and TFAP2B for MCC, and CEACAM6 for SCLC, show high specificity and sensitivity in immunostaining, suggesting their potential in improving diagnostic accuracy.*